Applicants : Rina Aharoni et al.

U.S. Serial No.: 09/768,872

August 22, 2003 Amendment under 37 C.F.R. § 1.116

Page 9

conceive of pharmaceutical compositions containing such terpolymers as recited in now-canceled claims 1-4.

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

To ensure compliance with their duty of disclosure under 37 C.F.R. §1.56, applicants wish to draw the Examiner's attention to the fact that their substitute specification filed January 23, 2001, in addition to deleting certain disclosure, deleted a cross-reference to U.S. Provisional Application No. 60/123,675, filed March 9, 1999, which cross-reference was present in the originally filed specification. On August 1, 2001, applicants filed a Declaration and Power of Attorney claiming the benefit of U.S. Provisional Application Nos. 60/093,859, filed July 23, 1998, 60/101,825, filed September 25, 1998, 60/102,960, filed 1998, 60/106,350, filed October 30, October 2, 1998, 60/108,184, filed November 12, 1998, but not of U.S. Provisional A copy of U.S. Provisional Application No. 60/123,675. Application No. 60/123,675 is attached hereto as **Exhibit 1** and a PTO Form-1449 listing U.S. Provisional Application No. 60/123,675 is attached hereto as Exhibit A.

The claim to the benefit of U.S. Provisional Application No. 60/123,675 has been made in U.S. Serial No. 09/359,099, filed July 22, 1999, which was disclosed in applicants' June 26, 2002 Information Disclosure Statement in connection with the subject application. U.S. Serial No. 09/359,099 lists a different inventive entity², is assigned to a different entity³ and is prosecuted by a different attorney from the subject application. Applicants are aware of U.S. Serial No. 09/359,099 by virtue of

² Jack L. Strominger and Masha Fridkis-Hareli ³ The President and Fellows of Harvard College

Applicants : Rina Aharoni et al.

U.S. Serial No.: 09/768,872

August 22, 2003 Amendment under 37 C.F.R. § 1.116

Page 10

an agreement between the licensee of the subject application and the assignee of U.S. Serial No. 09/359,099.

Allowable Subject Matter

The Examiner stated that claims 16-20 and 32-39 contain allowable subject material.

Accordingly, applicants maintain that the application is now in condition for allowance and earnestly solicit a notice of allowance of claims 16-20, 32-39 and 157-165.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$110.00 for the one-month extension of time, is deemed necessary in connection with the filing of this Amendment. However, if any additional fee is deemed necessary, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,

ohn P. White Reg. No. 28,678 Date

03

John P. White

Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400



Page 1 of 1 Serial No. Atty. Docket No. Form PTO-1449 **U.S. Department of Commerce** 60772-PCT-US/ 09/768,872 Patent and Trademark Office JPW/ GJG/CSN INFORMATION DISCLOSURE CITATION Applicants: Rina Aharoni et al. (Use several sheets if necessary) Group Art Unit Filing Date 1644 January 23, 2001 U.S. PATENT DOCUMENTS Filing Date Class Subclass Document Number Date Name Examiner if Appropriate Initial 03/09/99 US Strominger et al. 60 1 FOREIGN PATENT DOCUMENTS Translation Class Subclass Date **Country** Document Number Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) DATE CONSIDERED EXAMINER

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.